Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.
Joseph J ZhaoDominic Wei Ting YapYiong Huak ChanBenjamin Kye Jyn TanChong Boon TeoNicholas Li-Xun SynElizabeth C SmythYu Yang SoonRaghav SundarPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Using KMSubtraction, data of PD-L1 subgroups previously unreported by primary manuscripts of pivotal clinical trials were retrieved. These data suggest the lack of benefit in the addition of ICI to chemotherapy in low PD-L1-expressing GEAC tumors.